Medication leaflets

Active substance

Results for the substance trastuzumab

14 results

About this active substance

Trastuzumab is a humanized monoclonal antibody used in the treatment of HER2-positive breast cancer and other cancers that overexpress the HER2 receptor. It works by binding to the HER2 receptor on the surface of tumor cells, inhibiting cellular signaling and promoting cancer cell destruction through immune mechanisms.

Trastuzumab is administered intravenously or subcutaneously, often in combination with other therapies such as chemotherapy. The duration of treatment and frequency of administration depend on the stage of the disease and the patient's response.

Common side effects include fever, chills, nausea, diarrhea, and fatigue. In rare cases, severe adverse reactions such as heart failure, severe allergic reactions, or pulmonary toxicity may occur. Careful monitoring of cardiac function is essential during treatment.

Trastuzumab is an innovative therapeutic option for patients with HER2-positive cancer, contributing to improved survival and quality of life.